A.R.T. Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

A.R.T. Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-4,625	Closed	-$208K	–	1290
2018 Q4	$208K	Sell	4,625 -1,400	-23%	-$73.4K	0.01%	1053
2018 Q3	$340K	Sell	6,025 -1,900	-24%	-$116K	0.02%	997
2018 Q2	$529K	Sell	7,925 -18,200	-70%	-$1.14M	0.02%	897
2018 Q1	$1.52M	Buy	+26,125	New	+$1.66M	0.06%	502
2017 Q2	–	Sell	-10,400	Closed	-$514K	–	1382
2017 Q1	$514K	Buy	+10,400	New	+$584K	0.02%	796
2016 Q2	–	Sell	-26,093	Closed	-$878K	–	1343
2016 Q1	$878K	Buy	+26,093	New	+$885K	0.04%	637
2015 Q1	–	Sell	-37,088	Closed	-$2.09M	–	1412
2014 Q4	$2.09M	Buy	37,088 +13,024	+54%	+$574K	0.08%	382
2014 Q3	$680K	Buy	24,064 +10,629	+79%	+$319K	0.03%	638
2014 Q2	$462K	Sell	13,435 -10,371	-44%	-$325K	0.02%	809
2014 Q1	$746K	Buy	+23,806	New	+$632K	0.04%	608

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

ICOM

Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

A.R.T. Advisors's ANIP Position: Q1 2019 in Review

A.R.T. Advisors sold out of ANI Pharmaceuticals (ANIP) in Q1 2019, closing a stake of 4,625 shares — an estimated $208K sold.

A.R.T. Advisors first reported a position in ANIP in Q1 2014 and held it in 10 quarters. The position peaked at $2.09M in Q4 2014. 190 funds tracked by Wall St. Rank hold ANIP as of Q1 2019.

A.R.T. Advisors reported no remaining ANI Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
A.R.T. Advisors sold 4,625 ANI Pharmaceuticals shares in Q1 2019, an estimated $208K.
A.R.T. Advisors first reported a position in ANI Pharmaceuticals in Q1 2014 and held it in 10 quarters.
A.R.T. Advisors's ANI Pharmaceuticals position peaked at $2.09M in Q4 2014.
190 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2019.

Based on A.R.T. Advisors's 13F filing for Q1 2019, filed 15 May 2019.